Histone deacetylases: Novel targets for prevention of colitis-associated cancer in mice

Gut

Volumn 57, Issue 5, 2008, Pages 613-622

  Glauben, R ^a   Batra, A ^a   Stroh, T ^a   Erben, U ^a   Fedke, I ^a   Lehr, H A ^b   Leoni, F ^c   Mascagni, P ^c   Dinarello, C A ^d   Zeitz, M ^a   Siegmund, B ^a,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^c Italfarmaco SpA   (Italy)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [6 (DIETHYLAMINOMETHYL)NAPHTH 2 YLMETHYLOXYCARBAMOYL]BENZOHYDROXAMIC ACID; AZOXYMETHANE; DEXTRAN SULFATE; GAMMA INTERFERON; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; ITF 2357; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PREVENTION; COLITIS; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; EXPERIMENTAL MODEL; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; LAMINA PROPRIA; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; APOPTOSIS; COLITIS; COLONIC NEOPLASMS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B;

EID: 42549114401     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.134650     Document Type: Article

References (38)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
2. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
3. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
4. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21:491-501.
5. Spencer VA, Davie JR. Role of covalent modifications of histones in regulating gene expression. Gene 1999;240:1-12.
6. Mishra N, Reilly CM, Brown DR, et al. Histone deacetylase inhibitors modulate renal disease in the MLR-lpr/lpr mouse. J Clin Invest 2003;111:539-52.
7. Kiernan B, Bres V, Ng RW, et al. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 2003;278:2758-66.
8. Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nature Rev Cancer 2001;1:194- 202.
9. Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 2005;10:197-204.
10. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-70.
11. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-6.
12. Richon VM, Zhou X, Rifkind RA, et al. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis 2001;27:260-4.
13. Leoni F, Zaliani A, Bertolini G, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002;99:2995-3000.
14. Reilly CM, Mishra N, Miller JM, et al. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol 2004;173:4171-8.
15. Chung YL, Lee MY, Wang AJ, et al. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003;8:707-17.
16. Glauben R, Batra A, Fedke I, et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006;176:5015-22.
17. Leoni F, Fossati G, Lewis EC, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005;11:1-15.
18. Tanaka T, Kohno H, Suzuki R, et al. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003;94:965-73.
19. Hegazi RA, Mady HH, Melhem MF, et al. Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice. Inflamm Bowel Dis 2003;9:230-6.
20. Becker C, Fantini MC, Wirtz S, et al. In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy. Gut 2005;54:950-4.
21. Siegmund B, Lehr HA, Fantuzzi G. Leptin: a pivotal mediator of intestinal inflammation in mice. Gastroenterology 2002;122:2011- 25.
22. Siegmund B, Lehr HA, Fantuzzi G, et al. IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA 2001;98:13249-54.
23. Kis A, Yellon DM, Baxter GF. Role of nuclear factor-kappa B activation in acute ischaemia-reperfusion injury in myocardium. Br J Pharmacol 2003;138:894-900.
24. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-59.
25. Siegmund B, Rieder F, Albrich S, et al. Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther 2001;296:99-105.
26. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
27. Siegmund B, Fantuzzi G, Rieder F, et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 2001;281:R1264-73.
28. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
29. Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996;98:1010-20.
30. Messi M, Giacchetto I, Nagata K, et al. Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol 2003;4:78-86.
31. Gilmore TD, Koedood M, Piffat KA, et al. Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene 1996;13:1367- 78.
32. Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007;446:557-61.
33. Shibata W, Maeda S, Hikiba Y, et al. Cutting edge: the IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol 2007;179:2681-5.
34. Chen L, Fischle W, Verdin E, et al. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 2001;293:1653-7.
35. Ashburner BP, Westerheide SD, Baldwin AS Jr. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001;21:7065-77.
36. Imre G, Gekeler V, Leja A, et al. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res 2006;66:5409- 18.
37. Liu H, Chen Y, Cui G, et al. Trichostatin A regulates hGCN5 expression and cell cycle on daudi cells in vitro. J Huazhong Univ Sci Technolog Med Sci 2006;26:534-7.
38. Takada Y, Gillenwater A, Ichikawa H, et al. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 2006;281:5612-22.